The Coler Lab at Seattle Children’s Research Institute is using their expertise to support the clinical trial of an experimental coronavirus vaccine funded by National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. The trial is being conducted at the Kaiser Permanente Washington Health Research Institute in Seattle, part of NIAID’s Infectious Diseases Clinical Research Consortium.
It is the first trial with people of any vaccine for SARS-CoV-2. In collaboration with Kaiser, Dr. Rhea Coler, Affiliate Professor, Global Health, and a senior investigator in the Center of Global Infectious Disease Research, is leading a team of Seattle Children’s researchers who will isolate cells and plasma from the blood samples of study participants receiving the experimental vaccine.
Read the story at Seattle Children's.